Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation.



  • Largest European fund investing in early- and growth-stage life science companies
  • Raised €534 million ($630 million) Jeito I fund from leading global investors including Temasek, Sanofi, the European Investment Fund (EIF), the Teacher Retirement System of Texas (TRS) and AXA

$630 million

Jeito Fund I close



  • Develop and implement all external and internal communications strategies and materials including for key international trade and digital media
  • Lead all comms including stakeholder comms and Jeito’s local French comms agency
  • Media management before, during and after key announcements



  • Broad coverage across international trade and business media including WSJ Venture Pro Capital, Endpoints and BioCentury
  • Raised international profile with key messages reflected across coverage and comms materials